On May 28, 2026 Sapu Nano and Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") reported that Vuong Trieu, Chief Executive Officer, reported it will present the Company’s Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will focus on Oncotelic’s development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics that are otherwise difficult or impossible to formulate using conventional technologies.
The Deciparticle platform is based on proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The Company believes the platform may enable improved aqueous compatibility, reduced reliance on toxic excipients, enhanced manufacturability, and broader development flexibility for challenging compounds.
At BIO 2026, the Company plans to highlight development progress across multiple Deciparticle programs, including:
Sapu006, a polysorbate-free intravenous docetaxel formulation currently moving into Phase 1b clinical evaluation;
Sapu003, an intravenous everolimus nanomedicine program designed to potentially reduce gastrointestinal exposure associated with oral administration currently in a global Phase 1b clinical trial; and
Broader applications of the Deciparticle platform for difficult-to-formulate small molecules and macrolide therapeutics.
The Company will also discuss how artificial intelligence and knowledge-organization technologies are being integrated into formulation development, manufacturing intelligence, and translational oncology workflows through its PDAOAI platform.
"Many important therapeutics remain limited by formulation complexity, poor aqueous solubility, excipient-related toxicity, or manufacturing challenges," said Vuong Trieu, Chief Executive Officer. "Our objective with Deciparticle is to create a scalable nanomedicine platform capable of enabling intravenous delivery of highly insoluble molecules while simplifying formulation architecture and supporting clinical translation."
According to the Company, Deciparticle formulations are designed to address key limitations associated with conventional solubilizing systems, including hypersensitivity reactions, surfactant burden, formulation instability, and manufacturing complexity.
Oncotelic believes the combination of nanomedicine engineering, translational oncology, manufacturing expertise, and AI-driven scientific cognition may provide a differentiated platform for future drug development.
BIO International Convention is one of the biotechnology industry’s largest partnering and innovation events, bringing together biotechnology companies, pharmaceutical companies, investors, and scientific leaders from around the world.
About Deciparticle
Deciparticle is Oncotelic’s proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.
(Press release, Oncotelic, MAY 28, 2026, View Source [SID1234666157])